Competitive intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are planning a new drug or are already an established presence in the market. Alongside R&D, CI is crucial to businesses that want to maximize the value of their science.
In this white paper, Ben Doran and Jeanne Penn draw on their experiences in the pharmaceutical field to explain how insights can be targeted to maximize the return on investment. This is critical in the biotech business because focusing on meaningful differentiation sets the foundation for value creation.
Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has produced a white paper that details five essential elements for running effective virtual workshops.
Pharma in the post-COVID era – adapting to the new normal is the latest whitepaper from Prescient, providing a comprehensive view of the state of the industry today, its response to COVID-19 and how the future looks for the industry as a whole.
Prescient’s thought leaders address major shifts in the landscape and outline near-, medium- and long-term choices facing pharma strategy leaders.
Content and offerings are evolving – so should your approach to maximize insights.
Prescient has conducted research among competitive intelligence (CI) stakeholders throughout the biopharmaceutical industry to identify the top challenges in CI and to highlight the strategic imperatives and actionable recommendations to face these challenges head-on. We developed a white paper to summarize the research and provide our insights and expertise.
In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market and how biopharmaceutical companies can optimize the performance of their brands. We discuss the impact and implications of these industry trends on brand teams and the strategies they can leverage to maximize their products’ potential. The following key trends have emerged:
With regulatory approval, CAR-T cell therapy must address significant unmet needs in clinical practice without restrictions in order to be successful.
San Francisco
+1 415 230 8460New York
+1 973 347 7750Boston
+1 857 341 0341London
+44 20 8832 7900New Delhi
+91 11 7127 91701Beijing
+86 10 6562 9095
© 2021 Prescient Healthcare Group.
Subscribe to our Insights
LinkedIn
Twitter
Facebook